Vitassay Healthcare, S.L.U. news

Despite the slow evolutionary rate of SARS-CoV-2 relative to other RNA viruses, its massive and rapid transmission during the COVID-19 pandemic has enabled it to acquire significant genetic diversity since it first entered the human population. This led to the emergence of numerous variants, some of them recently being labeled “variants of concern” (VOC), due to their potential impact on transmission, morbidity/mortality, and the evasion of neutralization by antibodies elicited by

The new Vitassay Real Time PCR allows the qualitative detection of SARS-CoV-2 and the HV 69/70 deletion of the S gene for SARS-CoV-2 in respiratory samples.

Several SARS-CoV-2 variants of concern (VOC) have emerged in the past months and monitoring them in all countries is key. The United Kingdom (UK) has detected a new variant of SARS-CoV-2 from samples initially taken in Kent on September 20th and London on September 21st, 2020, which was found associated with increased transmissibi

The new Vitassay SARS-CoV-2 + Flu A + B + RSV + Adeno Resp. is a rapid, immunochromatographic assay for the simultaneous qualitative detection of nucleoprotein antigen of SARS-CoV-2, Influenza type A, Influenza type B, RSV and Adenovirus from nasopharyngeal swabs samples from patients suspected of COVID-19 infection and/or Influenza A and/or Influenza B and/or Respiratory Syncytial Virus (RSV) and/or Adenovirus infection.

Clinically, patients with 

The new Vitassay SARS-CoV-2 is a rapid, immunochromatographic, one step assay for the qualitative detection of SARS-CoV-2 from nasopharyngeal samples. Simple and highly sensitivity immunoassay for professional in vitro use only.

SARS-CoV-2 infection can affect individuals of any age. The disease currently causes an overwhelming hospitalization of infected patients, presenting symptoms such as fever, dry cough, anosmia, fatigue, dypsnea, headache, dia